Etc-1002, a Modulator of Adenosine Monophosphate-Activated Protein Kinase and Adenosine Triphosphate-Citrate Lyase, Was Safe and Reduced Low-Density Lipoprotein-Cholesterol in Healthy Volunteers

Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia

“…26 The pharmacokinetics of ETC-1002 seem to make it suitable for once-daily administration. MacDougall et al 27 reported in a phase I study that used doses between 20 and 220 mg/d, a directly proportional increase in the maximum plasma concentration and 24-hour area under the curve with increasing doses of ETC-1002. The mean half-life of the drug ranged between 16 and 33 hours across the dosing range.…”